HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

fezolinetant

a neurokinin-3 receptor antagonist. A nonhormonal medication for treating menopausal hot flashes.

Also Known As:

ESN364; veozah

Networked: 10 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Thiadiazoles: 99
        fezolinetant: 10
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - fezolinetant: 10
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - Thiadiazoles: 99
      - fezolinetant: 10

Experts

1.	Combalbert, Jean: 2 articles (01/2021 - 12/2019)
2.	Fraser, Graeme L: 2 articles (01/2021 - 12/2019)
3.	Hoveyda, Hamid R: 2 articles (01/2021 - 12/2019)
4.	Ramael, Steven: 2 articles (01/2021 - 12/2019)
5.	Timmerman, Dirk: 2 articles (01/2021 - 12/2019)
6.	Kaku, Seiji: 1 article (08/2021)
7.	Ohtake, Akiyoshi: 1 article (08/2021)
8.	Tahara, Atsuo: 1 article (08/2021)
9.	Takamatsu, Hajime: 1 article (08/2021)
10.	Tanaka-Amino, Keiko: 1 article (08/2021)

Related Diseases

1.	Hot Flashes 01/01/2023 - "We conducted a phase 3, randomized, double-blind, 52-week safety study (SKYLIGHT 4 [Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause]) of placebo, fezolinetant 30 mg, and fezolinetant 45 mg once daily (1:1:1). " 09/01/2023 - "Fezolinetant for menopausal hot flashes and night sweats." 01/01/2023 - "NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes. " 01/01/2023 - "Women aged 40-65 years with an average of seven or more moderate-to-severe hot flashes per day were randomly assigned (1:1:1) to once-daily exact-matched placebo, fezolinetant 30 mg, or fezolinetant 45 mg. Randomisation was done using a web-based interactive response system and investigators, project team members, clinical staff, and participants were masked to treatment assignment. "
2.	Neoplasms (Cancer) 01/01/2023 - "Endometrial malignancy occurred in 1 of 210 in the fezolinetant 30-mg group (0.5%; 95% CI 2.2%) with no cases in the other groups. " 11/04/2023 - "Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant."
3.	Chemical and Drug Induced Liver Injury 01/01/2023 - "Liver enzyme elevations more than three times the upper limit of normal occurred in 6 of 583 placebo, 8 of 590 fezolinetant 30 mg, and 12 of 589 fezolinetant 45 mg participants; no Hy's law cases were reported (ie, no severe drug-induced liver injury with alanine aminotransferase or aspartate aminotransferase more than three times the upper limit of normal and total bilirubin more than two times the upper limit of normal, with no elevation of alkaline phosphatase and no other reason to explain the combination). "
4.	Hyperandrogenism 01/01/2021 - "Fezolinetant had a sustained effect to suppress hyperandrogenism and reduce the LH-to-FSH ratio in women with PCOS."
5.	Weight Loss (Weight Reduction) 01/01/2023 - "Recommended: Cognitive-behavioral therapy, clinical hypnosis, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant (Level I); oxybutynin (Levels I-II); weight loss, stellate ganglion block (Levels II-III). "

Related Drugs and Biologics

1.	Neurokinin-3 Receptors
2.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
3.	Serotonin (5 Hydroxytryptamine)
4.	Norepinephrine (Noradrenaline)
5.	Enzymes
6.	Bilirubin
7.	Aspartate Aminotransferases (Aspartate Transaminase)
8.	Transaminases (Aminotransferases)
9.	Alkaline Phosphatase
10.	Alanine Transaminase (SGPT)

Related Therapies and Procedures

1.	Hypnosis (Mesmerism)